Health and Fitness Health and Fitness
Wed, November 16, 2011
Tue, November 15, 2011
Mon, November 14, 2011
Sun, November 13, 2011
Sat, November 12, 2011
Fri, November 11, 2011
Thu, November 10, 2011
Wed, November 9, 2011
Tue, November 8, 2011
[ Tue, Nov 08th 2011 ] - Market Wire
30 AM EST
Mon, November 7, 2011
[ Mon, Nov 07th 2011 ] - Market Wire
30 a.m. ET
Sun, November 6, 2011
Sat, November 5, 2011
Fri, November 4, 2011

Exelixis Announces November 15th Webcast of Presentation at the Lazard Capital Markets 8th Annual Healthcare Conference


//health-fitness.news-articles.net/content/2011/ .. al-markets-8th-annual-healthcare-conference.html
Published in Health and Fitness on Thursday, November 10th 2011 at 13:34 GMT by Market Wire   Print publication without navigation


SOUTH SAN FRANCISCO, Calif.--([ BUSINESS WIRE ])--Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael Morrissey, Ph.D., the companyas president and chief executive officer, will present at the Lazard Capital Markets 8th Annual Healthcare Conference at 10:00 a.m. EST / 7:00 a.m. PST on Tuesday, November 15, 2011, in New York. Dr. Morrissey will provide a general business update, review the most recent publicly available data for cabozantinib, and discuss the pivotal trial plans and regulatory strategy for the compound.

The presentation will be webcast and may be accessed in the Event Calendar page under Investors at [ www.exelixis.com ].

About Exelixis

Exelixis, Inc. is a biotechnology company committed to developing small molecule therapeutics for the treatment of cancer. Exelixis is focusing its proprietary resources and development efforts exclusively on cabozantinib, its most advanced solely-owned product candidate, in order to maximize the therapeutic and commercial potential of this compound. Exelixis believes cabozantinib has the potential to be a high-quality, differentiated pharmaceutical product that can make a meaningful difference in the lives of patients. Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs. For more information, please visit the company's web site at [ www.exelixis.com ].


Publication Contributing Sources